Investors & Media Overview


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Learn More

Press Releases

06-Jun-23

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP Data show that inhibiting Orai1-mediated store-operated Ca 2+ entry (SOCE) with a selective CRAC channel inhibitor prevented the progression of RAP and
23-May-23

CalciMedica Expands Executive Team with New Appointments

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development LA JOLLA, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing
15-May-23

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended
View All News